2024-02-012025-01-312025-01-31false11139515MAN PHARMA LIMITED2025-10-20falseiso4217:GBPxbrli:pure111395152024-01-31111395152025-01-31111395152024-02-012025-01-31111395152023-01-31111395152024-01-31111395152023-02-012024-01-3111139515bus:SmallEntities2024-02-012025-01-3111139515bus:AuditExempt-NoAccountantsReport2024-02-012025-01-3111139515bus:FullAccounts2024-02-012025-01-3111139515bus:PrivateLimitedCompanyLtd2024-02-012025-01-3111139515core:WithinOneYear2025-01-3111139515core:AfterOneYear2025-01-3111139515core:WithinOneYear2024-01-3111139515core:AfterOneYear2024-01-3111139515core:ShareCapital2025-01-3111139515core:SharePremium2025-01-3111139515core:RevaluationReserve2025-01-3111139515core:OtherReservesSubtotal2025-01-3111139515core:RetainedEarningsAccumulatedLosses2025-01-3111139515core:ShareCapital2024-01-3111139515core:SharePremium2024-01-3111139515core:RevaluationReserve2024-01-3111139515core:OtherReservesSubtotal2024-01-3111139515core:RetainedEarningsAccumulatedLosses2024-01-3111139515core:LandBuildings2025-01-3111139515core:PlantMachinery2025-01-3111139515core:Vehicles2025-01-3111139515core:FurnitureFittings2025-01-3111139515core:OfficeEquipment2025-01-3111139515core:NetGoodwill2025-01-3111139515core:IntangibleAssetsOtherThanGoodwill2025-01-3111139515core:ListedExchangeTraded2025-01-3111139515core:UnlistedNon-exchangeTraded2025-01-3111139515core:LandBuildings2024-01-3111139515core:PlantMachinery2024-01-3111139515core:Vehicles2024-01-3111139515core:FurnitureFittings2024-01-3111139515core:OfficeEquipment2024-01-3111139515core:NetGoodwill2024-01-3111139515core:IntangibleAssetsOtherThanGoodwill2024-01-3111139515core:ListedExchangeTraded2024-01-3111139515core:UnlistedNon-exchangeTraded2024-01-3111139515core:LandBuildings2024-02-012025-01-3111139515core:PlantMachinery2024-02-012025-01-3111139515core:Vehicles2024-02-012025-01-3111139515core:FurnitureFittings2024-02-012025-01-3111139515core:OfficeEquipment2024-02-012025-01-3111139515core:NetGoodwill2024-02-012025-01-3111139515core:IntangibleAssetsOtherThanGoodwill2024-02-012025-01-3111139515core:ListedExchangeTraded2024-02-012025-01-3111139515core:UnlistedNon-exchangeTraded2024-02-012025-01-3111139515core:MoreThanFiveYears2024-02-012025-01-3111139515core:Non-currentFinancialInstruments2025-01-3111139515core:Non-currentFinancialInstruments2024-01-3111139515dpl:CostSales2024-02-012025-01-3111139515dpl:DistributionCosts2024-02-012025-01-3111139515core:LandBuildings2024-02-012025-01-3111139515core:PlantMachinery2024-02-012025-01-3111139515core:Vehicles2024-02-012025-01-3111139515core:FurnitureFittings2024-02-012025-01-3111139515core:OfficeEquipment2024-02-012025-01-3111139515dpl:AdministrativeExpenses2024-02-012025-01-3111139515core:NetGoodwill2024-02-012025-01-3111139515core:IntangibleAssetsOtherThanGoodwill2024-02-012025-01-3111139515dpl:GroupUndertakings2024-02-012025-01-3111139515dpl:ParticipatingInterests2024-02-012025-01-3111139515dpl:GroupUndertakingscore:ListedExchangeTraded2024-02-012025-01-3111139515core:ListedExchangeTraded2024-02-012025-01-3111139515dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-02-012025-01-3111139515core:UnlistedNon-exchangeTraded2024-02-012025-01-3111139515dpl:CostSales2023-02-012024-01-3111139515dpl:DistributionCosts2023-02-012024-01-3111139515core:LandBuildings2023-02-012024-01-3111139515core:PlantMachinery2023-02-012024-01-3111139515core:Vehicles2023-02-012024-01-3111139515core:FurnitureFittings2023-02-012024-01-3111139515core:OfficeEquipment2023-02-012024-01-3111139515dpl:AdministrativeExpenses2023-02-012024-01-3111139515core:NetGoodwill2023-02-012024-01-3111139515core:IntangibleAssetsOtherThanGoodwill2023-02-012024-01-3111139515dpl:GroupUndertakings2023-02-012024-01-3111139515dpl:ParticipatingInterests2023-02-012024-01-3111139515dpl:GroupUndertakingscore:ListedExchangeTraded2023-02-012024-01-3111139515core:ListedExchangeTraded2023-02-012024-01-3111139515dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-02-012024-01-3111139515core:UnlistedNon-exchangeTraded2023-02-012024-01-3111139515core:NetGoodwill2025-01-3111139515core:IntangibleAssetsOtherThanGoodwill2025-01-3111139515core:LandBuildings2025-01-3111139515core:PlantMachinery2025-01-3111139515core:Vehicles2025-01-3111139515core:FurnitureFittings2025-01-3111139515core:OfficeEquipment2025-01-3111139515core:AfterOneYear2025-01-3111139515core:WithinOneYear2025-01-3111139515core:ListedExchangeTraded2025-01-3111139515core:UnlistedNon-exchangeTraded2025-01-3111139515core:ShareCapital2025-01-3111139515core:SharePremium2025-01-3111139515core:RevaluationReserve2025-01-3111139515core:OtherReservesSubtotal2025-01-3111139515core:RetainedEarningsAccumulatedLosses2025-01-3111139515core:NetGoodwill2024-01-3111139515core:IntangibleAssetsOtherThanGoodwill2024-01-3111139515core:LandBuildings2024-01-3111139515core:PlantMachinery2024-01-3111139515core:Vehicles2024-01-3111139515core:FurnitureFittings2024-01-3111139515core:OfficeEquipment2024-01-3111139515core:AfterOneYear2024-01-3111139515core:WithinOneYear2024-01-3111139515core:ListedExchangeTraded2024-01-3111139515core:UnlistedNon-exchangeTraded2024-01-3111139515core:ShareCapital2024-01-3111139515core:SharePremium2024-01-3111139515core:RevaluationReserve2024-01-3111139515core:OtherReservesSubtotal2024-01-3111139515core:RetainedEarningsAccumulatedLosses2024-01-3111139515core:NetGoodwill2023-01-3111139515core:IntangibleAssetsOtherThanGoodwill2023-01-3111139515core:LandBuildings2023-01-3111139515core:PlantMachinery2023-01-3111139515core:Vehicles2023-01-3111139515core:FurnitureFittings2023-01-3111139515core:OfficeEquipment2023-01-3111139515core:AfterOneYear2023-01-3111139515core:WithinOneYear2023-01-3111139515core:ListedExchangeTraded2023-01-3111139515core:UnlistedNon-exchangeTraded2023-01-3111139515core:ShareCapital2023-01-3111139515core:SharePremium2023-01-3111139515core:RevaluationReserve2023-01-3111139515core:OtherReservesSubtotal2023-01-3111139515core:RetainedEarningsAccumulatedLosses2023-01-3111139515core:AfterOneYear2024-02-012025-01-3111139515core:WithinOneYear2024-02-012025-01-3111139515core:Non-currentFinancialInstrumentscore:CostValuation2024-02-012025-01-3111139515core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-02-012025-01-3111139515core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-02-012025-01-3111139515core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-02-012025-01-3111139515core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-02-012025-01-3111139515core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-02-012025-01-3111139515core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-02-012025-01-3111139515core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-02-012025-01-3111139515core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-02-012025-01-3111139515core:Non-currentFinancialInstrumentscore:CostValuation2025-01-3111139515core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-3111139515core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-3111139515core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-3111139515core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-3111139515core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-3111139515core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-3111139515core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-3111139515core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-3111139515core:Non-currentFinancialInstrumentscore:CostValuation2024-01-3111139515core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-3111139515core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-3111139515bus:Director12024-02-012025-01-31

MAN PHARMA LIMITED

Registered Number
11139515
(England and Wales)

Unaudited Financial Statements for the Year ended
31 January 2025

MAN PHARMA LIMITED
Company Information
for the year from 1 February 2024 to 31 January 2025

Director

Issac, Abdullah

Registered Address

472 Greenford Road
Greenford
UB6 8SQ

Registered Number

11139515 (England and Wales)
MAN PHARMA LIMITED
Balance Sheet as at
31 January 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets35,6614,348
5,6614,348
Current assets
Stocks460,8566,787
Debtors521,47935,858
Cash at bank and on hand139,631126,149
221,966168,794
Creditors amounts falling due within one year6(39,004)(13,772)
Net current assets (liabilities)182,962155,022
Total assets less current liabilities188,623159,370
Net assets188,623159,370
Capital and reserves
Called up share capital11
Profit and loss account188,622159,369
Shareholders' funds188,623159,370
The financial statements were approved and authorised for issue by the Director on 20 October 2025, and are signed on its behalf by:
Issac, Abdullah
Director
Registered Company No. 11139515
MAN PHARMA LIMITED
Notes to the Financial Statements
for the year ended 31 January 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Plant and machinery15
Vehicles20
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees

20252024
Average number of employees during the year11
3.Tangible fixed assets

Plant & machinery

Vehicles

Total

£££
Cost or valuation
At 01 February 24-16,58716,587
Additions2,567-2,567
At 31 January 252,56716,58719,154
Depreciation and impairment
At 01 February 24-12,23912,239
Charge for year3858691,254
At 31 January 2538513,10813,493
Net book value
At 31 January 252,1823,4795,661
At 31 January 24-4,3484,348
4.Stocks

2025

2024

££
Finished goods60,8566,787
Total60,8566,787
5.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables21,1392,691
Other debtors-33,167
Prepayments and accrued income340-
Total21,47935,858
6.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables4,81516
Amounts owed to related parties2,000-
Taxation and social security31,66912,131
Other creditors5201,625
Total39,00413,772
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
7.Related party transactions
At the yearend, the company owed £2,000 (2024: NIL) to AIAM Ltd. The companies are related as Mr. Abdullah Issac is also the director of this company.